Last reviewed · How we verify
Selective serotonin re-uptake inhibitor
SSRIs block the reuptake of serotonin at the presynaptic neuron, increasing serotonin concentration in the synaptic cleft.
SSRIs block the reuptake of serotonin at the presynaptic neuron, increasing serotonin concentration in the synaptic cleft. Used for Major depressive disorder, Generalized anxiety disorder, Obsessive-compulsive disorder.
At a glance
| Generic name | Selective serotonin re-uptake inhibitor |
|---|---|
| Also known as | Pharmacotherapy, Escitalopram or Sertraline, SSRI, Antidepressant medication, Depression treatment |
| Sponsor | New Valley University |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| Target | Serotonin transporter (SERT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
By inhibiting the serotonin transporter (SERT), SSRIs prevent the reabsorption of serotonin from the synapse back into the presynaptic neuron. This increases the availability of serotonin to bind postsynaptic receptors, enhancing serotonergic neurotransmission. This mechanism is thought to underlie their efficacy in treating depression, anxiety disorders, and related conditions.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
- Obsessive-compulsive disorder
- Panic disorder
- Social anxiety disorder
- Post-traumatic stress disorder
Common side effects
- Nausea
- Headache
- Sexual dysfunction
- Insomnia or somnolence
- Diarrhea
- Tremor
- Dry mouth
Key clinical trials
- Study of Electrophysiological Markers of Antidepressants in Major Depressive Disorder (NA)
- Intradermal Acupuncture for Assisting SSRI Dose Reduction in Major Depressive Disorder (NA)
- Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease (PHASE2)
- Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms (PHASE3)
- A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)
- Effect of Virtual Reality on Depression in Adolescent Females (NA)
- MAGNESIUM & SSRI VS SSRI ALONE AMONG PATIENTS OF MAJOR DEPRESSIVE DISORDER (PHASE2)
- Pattern Separation in Major Depressive Disorder (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: